Although low-dose IL-2 administration transiently increases Treg numbers and has been used with some success to treat autoimmune diseases, systemic administration enhances Tregs nonspecifically and may also activate CD8+ T cells and NK cells. Here, IL2 is linked to autoimmune disease.